Syncona Ltd - London-based life science investor owns a diversified portfolio of companies spanning across clinical stages - Chair & Chief Executive Officer Chris Hollowood buys 89,588 shares at average price of GBP1.12, worth GBP99,980, in London on Monday. Read More
(Alliance News) - Syncona Ltd on Thursday offered up a resilient set of annual results, swinging to profit after a challenging year thanks in part to the strength of its life sciences portfolio. Read More
(Alliance News) - Syncona Ltd on Monday said it will provide further funding to a newly formed firm created after one of its portfolio companies acquired another. Read More
(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs. Read More
Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More
(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc. Read More
Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles. Read More
(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses. Read More
Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona. Read More
(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes. Read More
(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies. Read More
Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024. Read More
(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment. Read More
Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease. Read More
(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline". Read More
Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles. Read More